Bristol-Myers Squibb Co
‘Big Short’ Michael Burry hints we are in the center of a current market bubble popping akin to ’08 and ’00
“The Huge Small” investor Michael Burry, ideal regarded for contacting the subprime mortgage crisis, issued a further dire prediction in a cryptic tweet, hinting that a 2000 and 2008 style market place bubble could be on its way to popping in 2022. The founder of Scion Asset Management appeared to make a checklist for indicators of […]
Read More
Stocks making the biggest moves midday: Netflix, Pinduoduo, Catalent, Bristol-Myers and more
The Netflix logo is seen on a TV remote controller, in this illustration taken January 20, 2022. Dado Ruvic | Reuters Check out the companies making headlines in midday trading. Catalent Inc. – Shares of pharmaceutical company Catalent fell 8% after earnings that disappointed Wall Street. While Catalent beat expectations for earnings, its revenue and […]
Read More
Passage of Inflation Reduction Act gives Medicare historic new powers over drug prices
A pharmacist collects medications for prescriptions at a pharmacy. Simon Dawson | Bloomberg | Getty Images Medicare is poised to renegotiate the prices of some of its most expensive drugs through a historic expansion of its power, which could reduce costs for many seniors as well as federal spending on its prescription drug plan. The […]
Read More
Investor Sarat Sethi has some stock picks to play inflation and a consumer slowdown
Investors should stick to companies that can keep generating earnings as they navigate high inflation and a consumer slowdown, according to DCLA’s Sarat Sethi. “Earnings are going to drive this market going forward,” Sethi said Monday on CNBC’s “Squawk Box.” “Not multiple expansion, not liquidity, it’s going to be where do we find earnings, and […]
Read More
Artificial intelligence drug hunters are nearing a pivotal stage in their development
Efforts to use artificial intelligence to discover drugs have been underway for about a decade but industry watchers are predicting an inflection point is nearing for investors, who have been looking for ways to determine how AI-first drug developers should be valued. AI and machine learning offer the potential to speed up the hunt for […]
Read More
Having a woman in the boardroom or C-suite drives even wider diversity, study finds
shironosov | Getty Images If you want to take a good guess at a company’s gender diversity record, you might want to first look at who its CEO or board chair is, according to the findings of a new study. Having a female CEO at the helm of a company or chairing its board tends […]
Read More
Here’s Jim Cramer’s advice to navigate this uncertain earnings season
Earnings season is entering full swing on Wall Street, and CNBC’s Jim Cramer said Monday that investors would be wise to take a wait-and-see approach toward shares of companies that are about to report quarterly numbers. “In this environment, it’s always going to be fragile on the upside and easy on the downside, because the […]
Read More
Signs point to biotech M&A heating up, Wells Fargo says. Here’s where to look
The pace of biotech deals is likely to pick up, but investors should think about smaller targets, said Wells Fargo analyst Mohit Bansal. Bansal called out both enticing valuations for small- and mid-cap biotech companies, which are now trading at an enterprise value of about one times cash, on average, and a tough regulatory environment […]
Read More
Searching for value in the battered biotech sector, which may not have hit bottom yet
Investors have been laser-focused on profit-producing companies, which has left companies in their pre-revenue stage on the sidelines. As a result, a growing number of biotech stocks are now trading below the value of the cash on their balance sheets. Over the past year, the SPDR S & P Biotech ETF is down nearly 44%, […]
Read More
Stocks making the biggest moves premarket: Turning Point Therapeutics, Lululemon, RH and others
Check out the companies making headlines before the bell: Turning Point Therapeutics (TPTX) – The biopharmaceutical company’s shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share in cash, or $4.1 billion. Turning Point specializes in cancer treatments. Lululemon (LULU) – Lululemon shares rose […]
Read More